ArticleMedicine2026
Clinical characteristics and risk factors associated with mortality in hospitalized patients with COVID-19 aged 90 years or older.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Although the elderly population is significantly vulnerable to Corona Virus Disease 2019 (COVID-19) infection, research pertaining to this demographic remains relatively limited. Therefore, this study aimed to summarize the clinical characteristics, assess risk factors for death in hospitalized patients with COVID-19 aged ≥90 years, and provide insight into the treatment of severe/critically ill patients. This cross-sectional study was conducted at a tertiary hospital in Beijing, including patients aged ≥90 years hospitalized with COVID-19 from December 1, 2022, to February 28, 2023. We collected clinical data and used a multivariable logistic regression model to identify mortality risk factors. The calibration curve further confirmed the predictive capabilities of the model. The study included 150 patients, with 54 severe/critical cases and an overall in-hospital mortality rate of 31 (20.7%) patients. Multivariable logistic regression revealed a decreased lymphocyte percentage (odd ratio (OR) 0.81 [95% confidence interval (CI) 0.72-0.92], P = .001) and venous thrombosis of lower limbs (OR 5.49 [95% CI 1.56-19.35], P = .008) significantly increased mortality risk. Paxlovid use within 5 days of symptom onset (OR 0.20 [95% CI 0.04-0.95], P = .042) reduced the risk. A decreased lymphocyte percentage and venous thrombosis of the lower limbs were associated with an increased risk of death. Conversely, the use of Paxlovid was correlated with a reduced risk of death among patients with COVID-19 aged ≥90 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.